Who owns Faeth Therapeutics, Inc. (FTH)? Elite investor 13F holders
2 tracked elite investors reported holding Faeth Therapeutics, Inc as of 2026-06-30, including Caligan Partners, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | FAETH THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 15736675.00 USD | 629467.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | Sensei Biotherapeutics Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Renaissance Technologies LLC | FAETH THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 510400.00 USD | 20416.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.